¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"secondary leukaemia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® secondary infection ÇÑ±Û ÀÌÂ÷°¨¿°
¼³¸í   
  ¾î¶² º´¿øÃ¼ÀÇ °¨¿°¿¡ ÀÇÇÏ¿© º»ÀÎÀÇ ÀúÇ×·ÂÀÌ ¾àÇØÁ³À» ¶§ ¸öÀÇ ´Ù¸¥ ºÎÀ§·Î ÀüÀÌÇÏ¿© ´Ù½Ã °¨¿°À» ÀÏÀ¸Å°´Â °Í. º´¿øÃ¼°¡ ÀÎü¿¡ Ä§ÀÔÇÏ¿© Æ¯Á¤ÇÑ ±â°üÀ̳ª Á¶Á÷¿¡¼­ º´¿øÃ¼°¡ Áõ½ÄÇϰí, ±×°÷¿¡ Æ¯À¯ÀÇ º´Å͸¦ ÀÏÀ¸Å°´Â °ÍÀÌ 1Â÷°¨¿° ¶Ç´Â Ãʰ¨¿°ÀÌ´Ù. ÀÌ 1Â÷°¨¿°ÀÇ º´ÅÍÀÇ º´¿øÃ¼°¡ Ç÷°ü-¸²ÇÁ°ü-±â°ü-¼ÒÈ­°ü-¿ä°ü µîÀÇ ±æÀ» µû¶ó °°Àº ±â°üÀÇ ´Ù¸¥ ºÎÀ§³ª ´Ù¸¥ ±â°üÀ¸·Î ¿î¹ÝµÇ¾î °¨¿°À» ÀÏÀ¸Å²´Ù. µû¶ó¼­ 1Â÷°¨¿°¿¡ ÀÇÇÏ¿© ÃæºÐÇÑ ¸é¿ªÀÌ µÉ °æ¿ì¿¡´Â 2Â÷°¨¿°ÀÌ ÀϾÁö ¾Ê´Â´Ù. ¿¹¸¦ µé¾î, À¯Ç༺ °¨±â¿¡ °É·ÈÀ» ¶§ ¼¼±Õ¿¡ ÀÇÇÑ Æó·ÅÀÌ µÚµû¸£´Â °æ¿ì¸¦ À̸¥´Ù. Æó·Å±Õ, È­³ó¾Ë±Õ, ´ëÀå±Õ µûÀ§°¡ ÀÖ´Ù. 
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary
    1. ÀÌÂ÷- 2. Á¦2- 3. ¼Ó¹ß-
  • secondary amenorrhea
    ¼Ó¹ß¹«¿ù°æ
  • secondary aqueous
    Àç»ý¹æ¼ö, ÀÌÂ÷¹æ¼ö
  • secondary attack rate
    ÀÌÂ÷¹ßº´·ü
  • secondary biliary cirrhosis
    ¼Ó¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • secondary cardiomyopathy
    ÀÌÂ÷½ÉÀå±ÙÀ°º´(Áõ), ÀÌÂ÷½É±Ùº´(Áõ)
  • secondary constriction
    ÀÌÂ÷ÇùÂø
  • secondary culture
    ÀÌÂ÷¹è¾ç
  • secondary dentin
    ÀÌÂ÷»ó¾ÆÁú
  • secondary dentition
    ÀÌÂ÷Ä¡¾Æ
  • secondary disease
    ¼Ó¹ßº´, ¼Ó¹ßÁúȯ
  • secondary dysmenorrhea
    ¼Ó¹ß¿ù°æÅë
  • secondary ending
    ÀÌÂ÷Á¾¸»
  • secondary evoked response
    ÀÌÂ÷À¯¹ß¹ÝÀÀ
  • secondary gout
    ÀÌÂ÷Åëdz
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary sexual character
    ÀÌÂ÷¼ºÂ¡
  • secondary wound closure
    ÀÌÂ÷»óóºÀÇÕ
  • secondary dentition
    (¢¡permanent tooth) °£´Ï, ¿µ±¸Ä¡¾Æ
  • secondary hemostasis
    ÀÌÂ÷ÁöÇ÷
  • secondary infection
    ÀÌÂ÷°¨¿°
  • secondary nodule
    (¢¡germinal center) Á¾ÀÚÁß½É, ¹èÁß½É
  • secondary
    ÀÌÂ÷-, Á¦ÀÌ-, ¼Ó¹ß-
  • secondary suture
    ÀÌÂ÷ºÀÇÕ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary amenorrhea
    ÀÌÂ÷¹«¿ù°æ, ¼Ó¹ß¹«¿ù°æ
  • secondary aqueous
    Àç»ý¹æ¼ö, ÀÌÂ÷¹æ¼ö
  • secondary cardiomyopathy
    ÀÌÂ÷½ÉÀå±ÙÀ°º´Áõ
  • secondary constriction
    ÀÌÂ÷ÇùÂø
  • secondary contact
    ÀÌÂ÷Á¢ÃË
  • secondary culture
    µÎ¹øÂ°½É±â
  • secondary biliary cirrhosis
    ¼Ó¹ß¾µ°³°ü°£°æÈ­(Áõ)
  • secondary dentition
    (¢¡permanent tooth) °£´Ï, ¿µ±¸Ä¡¾Æ
  • secondary disease
    ¼Ó¹ßº´
  • secondary dysmenorrhea
    ÀÌÂ÷¿ù°æÅë
  • secondary ending
    ÀÌÂ÷Á¾¸»
  • secondary gout
    ÀÌÂ÷Åëdz
  • secondary hemorrhage
    ¼Ó¹ßÃâÇ÷, ÀÌÂ÷ÃâÇ÷
  • secondary hypertension
    ÀÌÂ÷°íÇ÷¾Ð
  • secondary hypogonadism
    ¼Ó¹ß»ý½Ä»ùÀúÇÏÁõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • haploid secondary gametocyte
    Ȭ¹è¼öüÀÌÂ÷»ý½Ä¼¼Æ÷
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunodeficiency syndrome, secondary
    ÀÌÂ÷¼º ¸é¿ª°áÇÌ ÁõÈıº, ¼Ó¹ß¼º ¸é¿ª°áÇÌ ÁõÈıº
  • infection, secondary
    ÀÌÂ÷°¨¿°
  • process, secondary (psychic)
    ÀÌÂ÷°úÁ¤.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute megakaryoblastic leukaemia
    ±Þ¼º°Å´ë¸ð±¸¼º¹éÇ÷º´
  • leukemia =leukaemia
    ¹éÇ÷º´.
  • leukemia =leukaemia
    ¹éÇ÷º´
  • secondary yolk sac [secondary vitelline sac]
    ÀÌÂ÷³­È²ÁÖ¸Ó´Ï
  • culture, secondary
    ÀÌÂ÷¹è¾ç
  • haploid secondary gametocyte
    Ȭ¹è¼öüÀÌÂ÷»ý½Ä¼¼Æ÷
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunodeficiency syndrome, secondary
    ÀÌÂ÷¼º ¸é¿ª°áÇÌ ÁõÈıº, ¼Ó¹ß¼º ¸é¿ª°áÇÌ ÁõÈıº
  • infection, secondary
    ÀÌÂ÷°¨¿°
  • lamellar membranous bone secondary membranous bone
    ÃþÆÇ¸·»À ÀÌÂ÷¸·»À
  • palatine process [secondary palate]
    ÀÔõÀåµ¹±â (ÀÌÂ÷ÀÔõÀå)
  • process, secondary (psychic)
    ÀÌÂ÷°úÁ¤.
  • secondary
    ÀÌÂ÷¼ºÀÇ
  • secondary
    ¼Ó¹ß¼º,ÀÌÂ÷,2±â
  • secondary X rays
    ÀÌÂ÷X¼±
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Secondary yolk sac [Secondary vitelline sac]
    ÀÌÂ÷³­È²ÁÖ¸Ó´Ï
    [¿¾ ¿ë¾î] ÀÌÂ÷³­È²³¶
  • Secondary segmental bronchus
    ±¸¿ª±â°üÁö°¡Áö
    [¿¾ ¿ë¾î] ÀÌÂ÷±¸±â°üÁö
  • Secondary tympanic membrane
    µÑ°°í¸·
    [¿¾ ¿ë¾î] Á¦ÀÌ°í¸·
  • Secondary spiral lamina
    µÑ°³ª¼±ÆÇ
    [¿¾ ¿ë¾î] Á¦2³ª¼±ÆÇ
  • Secondary fissure
    µÑ°ƴ»õ
    [¿¾ ¿ë¾î] Á¦2¿­
  • Secondary polar body
    ÀÌÂ÷±ØÃ¼
    [¿¾ ¿ë¾î] ÀÌÂ÷±ØÃ¼
  • Secondary oocyte
    ÀÌÂ÷³­¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­¸ð¼¼Æ÷
  • Secondary oocyte, Metaphase II
    ÀÌÂ÷³­¸ð¼¼Æ÷, ÀÌÂ÷°¨¼öºÐ¿­Áß±â
    [¿¾ ¿ë¾î] Á¦À̳­¸ð¼¼Æ÷,ÀÌÂ÷Áß±â
  • Secondary follicle
    ÀÌÂ÷³­Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­Æ÷
  • Secondary ovarian follicle
    ÀÌÂ÷³­Æ÷
    [¿¾ ¿ë¾î] ÀÌÂ÷³­Æ÷
  • Secondary visceral nucleus
    ÀÌÂ÷³»Àå½Å°æÇÙ
    [¿¾ ¿ë¾î] Á¦2Àå½Å°æÇÙ
  • Secondary abdominal implantation
    ÀÌÂ÷¹è¾ÈÂø»ó
    [¿¾ ¿ë¾î] ÀÌÂ÷Àûº¹ºÎÂø»ó
  • Secondary bone
    ÀÌÂ÷»À
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñ
  • Secondary osteon
    ÀÌÂ÷»À´ÜÀ§
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñ¿ø
  • Secondary osteogenic bud
    ÀÌÂ÷»À¹ß»ý½Ï
    [¿¾ ¿ë¾î] ÀÌÂ÷°ñÇü¼º¾Æ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary amebic meningoencephalitis
    ÀÌÂ÷¾Æ¸Þ¹Ù¼ö¸·³ú¿°
  • secondary echinococcosis
    ÀÌÂ÷Æ÷ÃæÁõ
  • secondary infection
    ÀÌÂ÷°¨¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary acidosis
    ÀÌÂ÷ »êÁõ(ì£ó­ß«ñø)
  • secondary active transport
    ÀÌÂ÷ ´Éµ¿¼ö¼Û(ì£ó­ÒöÔÑâÃáê)
  • secondary alkalosis
    ÀÌÂ÷(ì£ó­) ¾ËÄ®¸®Áõ(ñø)
  • secondary bile acid
    ÀÌÂ÷ ´ãÁó»ê(ì£ó­ÓÅñðß«)
  • secondary bond
    ÀÌÂ÷ °áÇÕ(ì£ó­Ì¿ùê)
  • secondary charge effect
    ÀÌÂ÷ ÇÏÀüÈ¿°ú(ì£ó­ùÃï³üùÍý)
  • secondary culture
    ÀÌÂ÷ ¹è¾ç(ì£ó­ÛÆå×)
  • secondary deficiency
    ÀÌÂ÷ °áÇÌ(ì£ó­ÌÀù¹)
  • secondary derived protein
    ÀÌÂ÷ À¯µµ´Ü¹éÁú(ì£ó­ë¯ÓôÓ±ÛÜòõ)
  • secondary electron
    ÀÌÂ÷ ÀüÀÚ(ì£ó­ï³í­)
  • secondary fluor
    ÀÌÂ÷ Çü±¤Á¦(ì£ó­û«ÎÃð¥)
  • secondary hydration shell
    ÀÌÂ÷(ì£ó­) ¼öÈ­ â©ûù ²®Áú
  • secondary ionization
    ÀÌÂ÷(ì£ó­) ÀÌ¿ÂÈ­(ûù)
  • secondary ion mass spectrometry
    ÀÌÂ÷ ÀÌ¿ÂÁú·®ºÐ±¤¹ý(ì£ó­òõÕáÝÂÎÃÛö)
  • secondary isotope effect
    ÀÌÂ÷ µ¿À§¿ø¼ÒÈ¿°ú(ì£ó­ÔÒêÈêªáÈüùÍý)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • secondary
    ÀÌÂ÷(¼º)ÀÇ, ¼Ó¹ß(¼º)ÀÇ
  • secondary anemia
    ¼Ó¹ß¼ººóÇ÷
  • secondary infection
    ÀÌÂ÷°¨¿°, ¼Ó¹ß°¨¿°
  • secondary lesion
    ÀÌÂ÷¼ºº´º¯, ÀÌÂ÷¹ßÁø, ¼Ó¹ßÁø
  • secondary ossification center
    ÀÌÂ÷°ñÈ­Áß½É
  • secondary pneumonia
    ¼Ó¹ß¼ºÆó·Å
  • secondary sex characteristic
    ÀÌÂ÷¼ºÂ¡
  • secondary sterility
    ¼Ó¹ßºÒÀÓ
  • secondary tuberculosis
    ÀÌÂ÷¼º°áÇÙ
  • secondary X-ray
    ÀÌÂ÷X¼±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SA salicylic acid; saline [solution]; salt added; sarcoidosis; sarcoma; scalenus anticus; secondary ame...
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
CPSC congenital paucity of secondary synaptic clefts [syndrome]; Consumer Products Safety Commission
HSH hypomagnesemia with secondary hypocalcemia
HSRD hypertension secondary to renal disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LSIMS Liquid secondary ion mass spectrometry
S Secondary
SIMS Secondary Ion Mass Spectrometry
SLC Secondary Lymphoid-tissue Chemokine
SP Secondary Polycythaemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • brain vesicle`s secondary
    ÀÌÂ÷ ³úÆ÷
    Èı⠹èÅ ºÐÈ­·Î Çü¼ºµÇ´Â ³× °³ÀÇ ³ú³¶À¸·Î¼­ Àü³ú·ÎºÎÅÍ ºÐÈ­µÇ´Â Á¾³ú¿Í °£³ú, ´É³ú·ÎºÎÅÍ ºÐÈ­µÇ´Â Èijú¿Í ¼ö³ú¸¦ Æ÷ÇÔÇÑ´Ù.
  • secondary activation
    ÀÌÂ÷Àû Ȱ¼º
  • secondary amine
    ÀÌÂ÷ ¾Æ¹Î
  • secondary anemia
    ¼Ó¹ß¼º ºóÇ÷
  • secondary bond
    ÀÌÂ÷ °áÇÕ
    ÀϹÝÀûÀ¸·Î ¼ö¼Ò °áÇÕ, ¹Ýµ¥¸£¹ß½º Èû µîÀ» ¸»ÇÏ¸ç °áÇÕ·ÂÀº ÀÏÂ÷ °áÇշ¿¡ ºñÇÏ¸é ¸Å¿ì ÀÛ´Ù
  • secondary caries
    ÀÌÂ÷ ¿ì½Ä
    ½ÉºÎ¿¡ ¹ÌÄ£ ¹ý¶ûÁú ¿ì½ÄÀÌ »ó¾ÆÁú °æ°è¸¦ ¿·À¸·Î ÆÛÁ®¼­ °Å²Ù·Î Ç¥¸éÂÊÀ¸·Î ÁøÇàÇÏ´Â ¿ì½Ä. ¿ì½ÄÀ» ÃæÀüÇÑ ÈÄ ±× º¯¿¬¿¡¼­ ´Ù½Ã ÀϾ´Â ¿ì½Ä.
  • secondary cementum
    ÀÌÂ÷ ¹é¾ÇÁú, Á¦2¹é¾ÇÁú
    ÀÏÂ÷ ¹é¾ÇÁú ÀÌÈÄ¿¡ Çü¼ºµÈ ¸ðµç ÃþÀ» °¡¸®Å°´Â ¿ë¾î. ¼¼Æ÷¼º ȤÀº ºñ¼¼Æ÷¼ºÀÌ´Ù.
  • secondary crown
    ¿Ü°ü
  • secondary dentin formation
    ÀÌÂ÷ »ó¾ÆÁú Çü¼º
    Åë»óÀûÀÎ ±â´ÉÀû ±×¸®°í ¿­ ÀûÀÎ Àڱؿ¡ ´ëÇÑ Á¡Â÷ÀûÀÎ Ãß°¡Àû »ó¾ÆÁú Çü¼ºÀÌ¸ç ¹æ»ç¼± »çÁø »óÀ¸·Î Ä¡°üºÎ »ó¾ÆÁú µÎ²²ÀÇ ±ÕÀÏÇÑ Áõ°¡ ¾ç»óÀ» º¸À̰í ÀÖ´Ù. ´ëºÎºÐÀÇ ¼ºÀο¡´Â ÀÌ·¯ÇÑ °úÁ¤ÀÌ Á¸ÀçÇϸç ÀÌÀÇ Á¤µµ´Â °³Àο¡ µû¶ó ´Ù¾çÇÏ´Ù. 2Â÷ »ó¾ÆÁúÀº Ä¡¾Æ Ç¥¸é¿¡¼­ Ä¡¼ö±îÁö ¿ì½Ä º´º¯ÀÌ ÁøÇàµÇ´Âµ¥ °É¸®´Â ½Ã°£°ú °Å¸®¸¦ Áõ°¡½ÃŰ°Ô µÈ´Ù. ¶ÇÇÑ Ä¡¼ö°¢°ú °°Àº Ç¥ÃþÀÇ Ä¡¼ö Á¶Á÷À» ¸ÍÃâ ÈÄ ¼ö³â À̳»¿¡ 2Â÷ »ó¾ÆÁú·Î ´ëÄ¡½ÃÅ´À¸·Î½á ¼öº¹ ½Ã¼ú ½Ã ±â°èÀûÀÎ Ä¡¼ö ³ëÃâ °¡´É¼ºÀ» °¨¼Ò½ÃŲ´Ù. ÇÑÆí Àڱؿ¡ ´ëÇÑ Ä¡¼öÀÇ ¹Î°¨¼ºÀ» °¨¼Ò½Ã۱⠶§¹®¿¡ Ä¡¼ö °Ë»ç¿Í Ä¡¾Æ ÁúȯÀÇ Áø´Ü ½Ã À̰ÍÀÌ °í·ÁµÇ¾î¾ß ÇÑ´Ù.
  • secondary diagnosis
    ÀÌÂ÷ Áø´Ü
  • secondary disorder
    ÀÌÂ÷ Àå¾Ö
  • secondary efflorescence
    ¼Ó¹ß¼º ¹ßÁø
  • secondary epithelization vestibuloplasty
    ÀÌÂ÷¼º »óÇÇÈ­ ±¸°­ ÀüÁ¤¼ú
  • secondary gain
    ÀÌÂ÷ À̵æ
    °£Á¢ÀûÀÎ À̵æÀ¸·Î¼­ º¸Åë Áúº´À̳ª ¼è¾àÀ¸·ÎºÎÅÍ ¾ò¾îÁø´Ù. À̰ÍÀº Àڽſ¡°Ô ÇØ·Î¿î Àǹ«³ª Ȱµ¿À» ÇÇÇϰí Åë»óÀûÀ¸·Î´Â µµ¿ÍÁÖÁö ¾Ê´Â »ç¶÷À¸·ÎºÎÅÍ ÁöÁö¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÑ´Ù.
  • secondary healing
    ÀÌÂ÷Àû Ä¡À¯, À̱â À¯ÇÕ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
secondary leukaemia A leukaemia arising from either previous chemotherapy or radiotherapy or as the development of a pre-existing condition, such as myelodysplasia.
Origin: Gr. Haima = blood
(13 Nov 1997)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
abelson leukaemia virus A defective murine leukaemia virus capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukaemia after superinfection with friend, moloney, or rauscher virus.
(12 Dec 1998)
Abelson murine leukaemia virus A retrovirus belonging to the Type C retrovirus group subfamily (family Oncovirinae) which is associated with leukaemia and produces in vitro transformation of mouse cells.
(05 Mar 2000)
accelerated phase of leukaemia Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase.
(12 Dec 1998)
acute granulocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
Origin: Gr. Haima = blood
(27 Sep 1997)
acute leukaemia <haematology> A rapidly progressive cancer of the blood of sudden onset and characterised by the uncontrolled proliferation of immature blood cells which take over the bone marrow and spill into the blood stream. If left untreated is fatal within a few weeks or months.
See: acute lymphoblastic leukaemia, acute myeloid leukaemia.
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphoblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting the type of white blood cell known as lymphocytes. Approximately 650 new cases are diagnosed every year in the UK and it is the most common form of childhood leukaemia.
Acronym: ALL
Origin: Gr. Haima = blood
(11 Nov 1997)
acute lymphocytic leukaemia <radiology> 95% of cases of leukaemia in children, bone changes in 50-70% of kids (vs. 10% in adults); seen as early as 1 month after onset of symptoms, wrists and knees most commonly affected, bony defects: metaphyseal radiolucent bands! (similar findings in scurvy, JRA, syphilis), osteolytic lesions, periosteal reaction, osteosclerosis
(12 Dec 1998)
acute monocytic leukaemia <haematology> The most common translocation in this disorder of poorly differentiated monocytic cells involves chromosome region 11q in a large percentage of cases.
The translocation involves a cellular oncogene, c-ets which is mapped to the 11q23-24 region. The most common translocations reported are t(6;11), t(9;11), t(11;17) and t(11;19), of which t(9;11) (p21-22;q23) is by far the most frequently detected and implicated in acute myeloid leukaemia. The cells express CD14 surface antigen, which is diagnostic of monocytic cells.
Acronym: AML
Classification: FAB M5
(07 Apr 1998)
acute myeloblastic leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myelogenous leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute myeloid leukaemia <haematology> A rapidly progressing cancer of the blood affecting immature cells of the bone marrow, usually of the white cell population. It is much more common in adults than in children.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Treatment includes chemotherapy and/or bone marrow transplant.
This leukaemia demonstrates granulocyte differentiation, eosinophilia and Auer rods and is associated with a reciprocal translocation between 8 and 21 (q22;q22), which is the most common translocation in acute myeloid leukaemia and is found more often in younger patients than in older patients. The oncogene involved in this translocation is AML1, which can be detected by Southern blot. Numerical abnormalities, particularly monosomy-7, trisomy-4, trisomy-8, trisomy-21, -Y, monosomy-7 and deletions of the long arms of chromosomes 5 and 7 are quite common in all acute myeloid leukaemia and not restricted to any one FAB classification. Many of these abnormalities are observed at diagnosis and at later stage disease, particularly after chemotherapy.
Prognosis is generally more favorable than in FAB-M2 patients showing no translocation, because the latter patients show better remission rates for longer periods of time. Immunophenotyping is useful in diagnosis and expression of one or more of the myeloid antigens CD13, CD14 or CD33 must be detected to make a diagnosis of acute myeloid leukaemia.
Acronym: AML
Incidence: 2,000 new cases per year in the UK.
Origin: Gr. Haima = blood
(07 Apr 1998)
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
acute promyelocytic leukaemia Leukaemia presenting as a severe bleeding disorder, with infiltration of the bone marrow by abnormal promyelocytes and myelocytes, a low plasma fibrinogen, and defective coagulation.
(05 Mar 2000)
adult T-cell leukaemia Lymph nodes show a mixture of small and large atypical cells which are polymorphic and express nuclear pleiomorphism. Adult T-cell leukaemia is caused by HTLV-1 and is rare in the US and Europe but common in Japan. Tumour cells express CD2, CD3, CD5 and lack CD7. The most common chromosome change reported in adult T-cell leukaemia is presence of the 14q + marker
(05 Mar 2000)
aleukaemic leukaemia Leukaemia in which abnormal (or leukaemic) cells are absent in the peripheral blood.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukaemia
    ¹éÇ÷º´
  • secondary
    Á¦ 2ÀÇ
  • post secondary education
    Áßµî °úÁ¤ ÈÄÀÇ ±³À°
  • secondary
    µÑ°ÀÇ;ÁßµîÀÇ;º¸Á¶ÀÚ;´ë¸®ÀÚ
  • secondary accent
    Á¦ 2¾×¼¾Æ®
  • secondary ballot
    °á¼± ÅõÇ¥
  • secondary base
    2·ç
  • secondary education
    Áßµî ±³À°
  • secondary industry
    Á¦ 2Â÷ »ê¾÷
  • secondary school
    Áßµî Çб³
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á